Renalytix PLC Result of AGM
19 December 2024 - 10:17PM
RNS Regulatory News
RNS Number : 7887Q
Renalytix PLC
19 December 2024
Renalytix plc
("Renalytix" or the
"Company")
Result of AGM
LONDON and NEW YORK, 19 December 2024
- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which
is commercialising the only FDA-approved and Medicare reimbursed
prognostic test to support early-stage risk assessment for chronic
kidney disease, announces that at the Annual General
Meeting ("AGM") held earlier today, all resolutions were duly
passed.
The results of the AGM are detailed
below:
|
|
For
|
% voted in
favour
|
Against
|
% voted against
|
Withheld
|
|
Ordinary
resolutions
|
|
|
|
|
|
|
1 Receive and adopt the UK 2024 Annual
Report
|
215,649,238
|
99.86%
|
298,365
|
0.14%
|
40,760
|
|
2 Approve Directors' Remuneration
Report
|
187,117,898
|
86.76%
|
28,544,007
|
13.24%
|
326,458
|
|
3 Ratify the selection of
CohnReznick
|
215,624,372
|
99.92%
|
178,413
|
0.08%
|
185,578
|
|
4 Reappoint PKF Littlejohn LLP as
Auditors
|
215,760,810
|
99.91%
|
184,281
|
0.09%
|
43,272
|
|
5 Authorise Board to determine auditors'
remuneration
|
215,474,022
|
99.86%
|
302,821
|
0.14%
|
211,520
|
|
6 Authorise the issue of shares under the 2020
Equity Incentive Plan with Non-Employee Sub-Plan
|
151,371,930
|
83.99%
|
28,863,246
|
16.01%
|
35,753,187
|
|
7 Authorise the Issue of Equity
|
151,554,272
|
83.99%
|
28,898,602
|
16.01%
|
35,535,489
|
|
|
|
|
|
|
|
|
Special
resolutions
|
|
|
|
|
|
|
8 Authorise Issue of Equity without Pre-emptive
Rights
|
151,648,214
|
84.04%
|
28,799,536
|
15.96%
|
35,540,613
|
|
9 Authorise Market Purchase of Ordinary
Shares
|
180,179,511
|
99.83%
|
305,940
|
0.17%
|
35,502,912
|
For further information,
please contact:
|
Renalytix plc
|
www.renalytix.com
|
|
James McCullough, CEO
|
Via
Walbrook PR
|
|
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020
7710 7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Oberon Capital
(Joint Broker)
|
Tel: 020
3179 5300
|
|
Mike Seabrook / Nick Lovering
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 /
07407 804 654
|
|
|
|
|
CapComm Partners
|
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About
Renalytix (www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an
artificial intelligence-enabled in vitro diagnostics company, focused
on optimizing clinical management of kidney disease to drive
improved patient outcomes. Renalytix has received FDA approval and
Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.
Unrecognized and uncontrolled kidney disease
remains one of the largest barriers to controlling cost and
suffering in the United States and the United Kingdom's medical
system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical
validation, kidneyintelX.dkd is the only
FDA-approved and Medicare reimbursed prognostic tool capable of
understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed
across large physician group practices and health systems in select
regions of the United States.
The over 10,000 patients that have been tested
by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In
patient populations where kidneyintelX.dkd has been deployed, a
demonstrated and significant increase in diagnosis, prognosis, and
treatment rates have been recorded. kidneyintelX.dkd now has full
reimbursement established by Medicare, the largest insurance payer
in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended
for use in the international chronic kidney disease clinical
guidelines (KDIGO).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGBBBDDDBBDGSC
Renalytix (LSE:RENX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Renalytix (LSE:RENX)
Historical Stock Chart
From Jan 2024 to Jan 2025
